Eli Lilly’s Olomorasib Secures Second FDA Breakthrough Designation For Cancer Therapy – Retail Expects LLY Stock To Hit Record High Soon

The FDA granted Breakthrough Therapy designation to Eli Lilly's Olomorasib for advanced pancreatic cancer.

This is the second FDA breakthrough designation for Olomorasib, a cancer therapy.

The designation may expedite the drug's development and review process.